Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model - Seite 2

NAD: No abnormality detected

This bacterium was chosen due to its immediate availability as a recognized sinusitis model. Streptococcus pneumoniae, a Gram-positive bacterium, is a leading cause of bacterial pneumonia and meningitis in the United States, and a common cause of bloodstream infections, also known as sepsis, ear and sinus infections.²

A total of 12 groups of 10 mice each were assessed to determine the effectiveness of R327 and R111 against S. pneumoniae. Three groups were treated with varying intranasal doses twice daily of R327 (50, 100, 500 mg/kg) and showed a significant dose-dependent antibacterial effect when compared to early infection and vehicle control (p<0.05).

Three groups of mice were treated with varying intravenous doses of R327 (100, 500, 1,000 mg/kg) which showed significant dose-dependent antibacterial effect when compared to early infection control and vehicle control (p<0.05). Furthermore, three groups from the 12 were treated with varying intravenous doses of R111 (50, 100, 250 mg/kg) which showed a significant dose-dependent antibacterial effect when compared to early infection control and vehicle control (p<0.05).

Azithromycin was the positive control in the study given twice daily at 200 mg/kg and showed bactericidal effect when compared to vehicle control at five-days post infection (p<0.05).

The Company’s R327 and R111 compounds showed significant antibacterial capability with no abnormalities detected and are expected to be subject to further expanded sinusitis studies in due course. In addition to these studies, the Company’s clinical activities with R327 continues to progress in the background and looks forward to updating shareholders in due course.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435 and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Recce’s new antibiotic compound, RECCE 435, has been formulated for oral use.